In addition, in a cross-trial analysis, Vaduganathan et al. compared the treatment effects of ARNI, BB, MRA, and SGLT2 inhibitor with ACE inhibitor/ARB and BB in chronic HFrEF derived from the EMPHASIS-HF, PARADIGM-HF, and DAPA-HF trials. The gene discussed is SLC5A2; the disease is hydrops fetalis.